BACKGROUND: Early treatment prevents progression of joint damage in rheumatoid arthritis (RA), but diagnosis in early disease is impeded by lack of appropriate diagnostic criteria. OBJECTIVE: To study the value of rheumatoid factor (RF), anti-cyclic citrullinated peptide autoantibodies (anti-CCP), and anti-RA33 autoantibodies for diagnosis of RA and prediction of outcome in patients with very early arthritis. METHODS: The prospective follow up inception cohort included 200 patients with very early (<3 months) inflammatory joint disease. Autoantibodies were measured at baseline and analysed in a tree based model which aimed at determining the added diagnostic value of testing for anti-CCP and anti-RA33 as compared with RF alone. RESULTS: RA was diagnosed in 102 patients, while 98 developed other inflammatory arthropathies. Receiver operator curve analysis showed an optimum cut off level for RF at 50 U/ml, above which anti-CCP and anti-RA33 had no additional diagnostic value. Remarkably, RF >or=50 U/ml and anti-CCP showed similar sensitivity and high specificity for RA, but overlapped considerably. Anti-RA33 was less specific and did not correlate with RF or anti-CCP. Among patients with RA, 72% showed at least one of these three autoantibodies, compared with 15% of non-RA patients. RF >or=50 U/ml and anti-CCP were predictors of erosive disease, whereas anti-RA33 was associated with mild disease. CONCLUSIONS: Stepwise autoantibody testing in early inflammatory joint disease, starting with RF, followed by anti-CCP (in patients with RF <50 U/ml), and finally anti-RA33, should be used as a sensitive and effective strategy for distinguishing patients with RA at high risk for poor outcome.
BACKGROUND: Early treatment prevents progression of joint damage in rheumatoid arthritis (RA), but diagnosis in early disease is impeded by lack of appropriate diagnostic criteria. OBJECTIVE: To study the value of rheumatoid factor (RF), anti-cyclic citrullinated peptide autoantibodies (anti-CCP), and anti-RA33 autoantibodies for diagnosis of RA and prediction of outcome in patients with very early arthritis. METHODS: The prospective follow up inception cohort included 200 patients with very early (<3 months) inflammatory joint disease. Autoantibodies were measured at baseline and analysed in a tree based model which aimed at determining the added diagnostic value of testing for anti-CCP and anti-RA33 as compared with RF alone. RESULTS:RA was diagnosed in 102 patients, while 98 developed other inflammatory arthropathies. Receiver operator curve analysis showed an optimum cut off level for RF at 50 U/ml, above which anti-CCP and anti-RA33 had no additional diagnostic value. Remarkably, RF >or=50 U/ml and anti-CCP showed similar sensitivity and high specificity for RA, but overlapped considerably. Anti-RA33 was less specific and did not correlate with RF or anti-CCP. Among patients with RA, 72% showed at least one of these three autoantibodies, compared with 15% of non-RApatients. RF >or=50 U/ml and anti-CCP were predictors of erosive disease, whereas anti-RA33 was associated with mild disease. CONCLUSIONS: Stepwise autoantibody testing in early inflammatory joint disease, starting with RF, followed by anti-CCP (in patients with RF <50 U/ml), and finally anti-RA33, should be used as a sensitive and effective strategy for distinguishing patients with RA at high risk for poor outcome.
Authors: Klaus P Machold; Tanja A Stamm; Gabriele J M Eberl; Valerie K P Nell; Attila Dunky; Martin Uffmann; Josef S Smolen Journal: J Rheumatol Date: 2002-11 Impact factor: 4.666
Authors: Annemarie L M A Jansen; Irene van der Horst-Bruinsma; Dirkjan van Schaardenburg; Rob J van de Stadt; Margret H M T de Koning; Ben A C Dijkmans Journal: J Rheumatol Date: 2002-10 Impact factor: 4.666
Authors: M M J Nielen; A R van der Horst; D van Schaardenburg; I E van der Horst-Bruinsma; R J van de Stadt; L Aarden; B A C Dijkmans; D Hamann Journal: Ann Rheum Dis Date: 2005-01-07 Impact factor: 19.103
Authors: Solbritt Rantapää-Dahlqvist; Ben A W de Jong; Ewa Berglin; Göran Hallmans; Göran Wadell; Hans Stenlund; Ulf Sundin; Walther J van Venrooij Journal: Arthritis Rheum Date: 2003-10
Authors: O Meyer; C Labarre; M Dougados; Ph Goupille; A Cantagrel; A Dubois; P Nicaise-Roland; J Sibilia; B Combe Journal: Ann Rheum Dis Date: 2003-02 Impact factor: 19.103
Authors: Klaus P Machold; Hans Peter Brezinsek; Burkhard F Leeb; Stephan Pflugbeil; Franz Rainer; Franz Singer; Martin Skoumal; Tanja A Stamm; Manfred Herold Journal: Wien Klin Wochenschr Date: 2008 Impact factor: 1.704
Authors: Jeremy Sokolove; Dannette S Johnson; Lauren J Lahey; Catriona A Wagner; Danye Cheng; Geoffrey M Thiele; Kaleb Michaud; Harlan Sayles; Andreas M Reimold; Liron Caplan; Grant W Cannon; Gail Kerr; Ted R Mikuls; William H Robinson Journal: Arthritis Rheumatol Date: 2014-04 Impact factor: 10.995
Authors: Mittermayer Santiago; Murray Baron; Kiyomitsu Miyachi; Marvin J Fritzler; M Abu-Hakima; S Leclercq; M Bell; M Hudson; J-P Mathieu; S Taillefer; N Jones; P Docherty; M Khraishi; J Markland; J Pope; D Robinson; D Smith; E Sutton Journal: Clin Rheumatol Date: 2007-06-15 Impact factor: 2.980
Authors: Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maxime Dougados; Paul Emery; Cecile Gaujoux-Viala; Simone Gorter; Rachel Knevel; Jackie Nam; Monika Schoels; Daniel Aletaha; Maya Buch; Laure Gossec; Tom Huizinga; Johannes W J W Bijlsma; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Cem Gabay; Juan Gomez-Reino; Marios Kouloumas; Tore K Kvien; Emilio Martin-Mola; Iain McInnes; Karel Pavelka; Piet van Riel; Marieke Scholte; David L Scott; Tuulikki Sokka; Guido Valesini; Ronald van Vollenhoven; Kevin L Winthrop; John Wong; Angela Zink; Désirée van der Heijde Journal: Ann Rheum Dis Date: 2010-05-05 Impact factor: 19.103